EBS Relative Valuation
EBS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, EBS is overvalued; if below, it's undervalued.
Historical Valuation
Emergent BioSolutions Inc (EBS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.60 is considered Undervalued compared with the five-year average of 14.00. The fair price of Emergent BioSolutions Inc (EBS) is between 194.59 to 224.65 according to relative valuation methord. Compared to the current price of 13.90 USD , Emergent BioSolutions Inc is Undervalued By 92.86%.
Relative Value
Fair Zone
194.59-224.65
Current Price：13.90
92.86%
Undervalued
4.21
PE
1Y
3Y
5Y
7.85
EV/EBITDA
Emergent BioSolutions Inc. (EBS) has a current EV/EBITDA of 7.85. The 5-year average EV/EBITDA is -670.55. The thresholds are as follows: Strongly Undervalued below -6790.50, Undervalued between -6790.50 and -3730.53, Fairly Valued between 2389.42 and -3730.53, Overvalued between 2389.42 and 5449.40, and Strongly Overvalued above 5449.40. The current Forward EV/EBITDA of 7.85 falls within the Historic Trend Line -Fairly Valued range.
4.33
EV/EBIT
Emergent BioSolutions Inc. (EBS) has a current EV/EBIT of 4.33. The 5-year average EV/EBIT is -6.18. The thresholds are as follows: Strongly Undervalued below -78.69, Undervalued between -78.69 and -42.44, Fairly Valued between 30.07 and -42.44, Overvalued between 30.07 and 66.32, and Strongly Overvalued above 66.32. The current Forward EV/EBIT of 4.33 falls within the Historic Trend Line -Fairly Valued range.
0.60
PS
Emergent BioSolutions Inc. (EBS) has a current PS of 0.60. The 5-year average PS is 0.90. The thresholds are as follows: Strongly Undervalued below -0.72, Undervalued between -0.72 and 0.09, Fairly Valued between 1.71 and 0.09, Overvalued between 1.71 and 2.52, and Strongly Overvalued above 2.52. The current Forward PS of 0.60 falls within the Historic Trend Line -Fairly Valued range.
5.09
P/OCF
Emergent BioSolutions Inc. (EBS) has a current P/OCF of 5.09. The 5-year average P/OCF is 5.83. The thresholds are as follows: Strongly Undervalued below -15.18, Undervalued between -15.18 and -4.67, Fairly Valued between 16.33 and -4.67, Overvalued between 16.33 and 26.83, and Strongly Overvalued above 26.83. The current Forward P/OCF of 5.09 falls within the Historic Trend Line -Fairly Valued range.
4.12
P/FCF
Emergent BioSolutions Inc. (EBS) has a current P/FCF of 4.12. The 5-year average P/FCF is 4.80. The thresholds are as follows: Strongly Undervalued below -22.33, Undervalued between -22.33 and -8.76, Fairly Valued between 18.37 and -8.76, Overvalued between 18.37 and 31.94, and Strongly Overvalued above 31.94. The current Forward P/FCF of 4.12 falls within the Historic Trend Line -Fairly Valued range.
Emergent BioSolutions Inc (EBS) has a current Price-to-Book (P/B) ratio of 1.13. Compared to its 3-year average P/B ratio of 0.62 , the current P/B ratio is approximately 83.13% higher. Relative to its 5-year average P/B ratio of 1.04, the current P/B ratio is about 8.33% higher. Emergent BioSolutions Inc (EBS) has a Forward Free Cash Flow (FCF) yield of approximately 0.21%. Compared to its 3-year average FCF yield of -49.73%, the current FCF yield is approximately -100.43% lower. Relative to its 5-year average FCF yield of -27.36% , the current FCF yield is about -100.78% lower.
1.13
P/B
Median3y
0.62
Median5y
1.04
0.21
FCF Yield
Median3y
-49.73
Median5y
-27.36
Competitors Valuation Multiple
The average P/S ratio for EBS's competitors is 36.30, providing a benchmark for relative valuation. Emergent BioSolutions Inc Corp (EBS) exhibits a P/S ratio of 0.60, which is -98.34% above the industry average. Given its robust revenue growth of -21.34%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of EBS increased by 23.56% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 4.92 to 9.26.
The secondary factor is the Revenue Growth, contributed -21.34%to the performance.
Overall, the performance of EBS in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
GPRK
GeoPark Ltd
7.24USD
3.13%
SMBK
SmartFinancial Inc
37.97USD
1.88%
VZLA
Vizsla Silver Corp
5.51USD
-5.33%
PACK
Ranpak Holdings Corp
5.99USD
4.90%
GOTU
Gaotu Techedu Inc
2.56USD
1.19%
HIFS
Hingham Institution For Savings
287.52USD
2.21%
OUST
Ouster Inc
27.97USD
8.83%
GMRE
Global Medical REIT Inc
35.21USD
0.89%
GEVO
Gevo Inc
2.02USD
2.02%
Frequently Asked Questions
Is Emergent BioSolutions Inc (EBS) currently overvalued or undervalued?
Emergent BioSolutions Inc (EBS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.60 is considered Undervalued compared with the five-year average of 14.00. The fair price of Emergent BioSolutions Inc (EBS) is between 194.59 to 224.65 according to relative valuation methord. Compared to the current price of 13.90 USD , Emergent BioSolutions Inc is Undervalued By 92.86% .
What is Emergent BioSolutions Inc (EBS) fair value?
EBS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Emergent BioSolutions Inc (EBS) is between 194.59 to 224.65 according to relative valuation methord.
How does EBS's valuation metrics compare to the industry average?
The average P/S ratio for EBS's competitors is 36.30, providing a benchmark for relative valuation. Emergent BioSolutions Inc Corp (EBS) exhibits a P/S ratio of 0.60, which is -98.34% above the industry average. Given its robust revenue growth of -21.34%, this premium appears unsustainable.
What is the current P/B ratio for Emergent BioSolutions Inc (EBS) as of Jan 08 2026?
As of Jan 08 2026, Emergent BioSolutions Inc (EBS) has a P/B ratio of 1.13. This indicates that the market values EBS at 1.13 times its book value.
What is the current FCF Yield for Emergent BioSolutions Inc (EBS) as of Jan 08 2026?
As of Jan 08 2026, Emergent BioSolutions Inc (EBS) has a FCF Yield of 0.21%. This means that for every dollar of Emergent BioSolutions Inc’s market capitalization, the company generates 0.21 cents in free cash flow.
What is the current Forward P/E ratio for Emergent BioSolutions Inc (EBS) as of Jan 08 2026?
As of Jan 08 2026, Emergent BioSolutions Inc (EBS) has a Forward P/E ratio of 4.21. This means the market is willing to pay $4.21 for every dollar of Emergent BioSolutions Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Emergent BioSolutions Inc (EBS) as of Jan 08 2026?
As of Jan 08 2026, Emergent BioSolutions Inc (EBS) has a Forward P/S ratio of 0.60. This means the market is valuing EBS at $0.60 for every dollar of expected revenue over the next 12 months.